FDA Looked To Arava’s Safety Experience In Gauging Aubagio’s Risks
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Agency’s assessment of teriflunomide for multiple sclerosis incorporated the known safety data for leflunomide, a chemically related drug with an extensive post-marketing record in rheumatoid arthritis. Despite hepatotoxicity and other safety concerns with the older drug, its clinical experience provided reassurance that Aubagio’s risks could be managed without a REMS.
You may also be interested in...
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Review Of Reviews: Drug Review Profiles 2013
Pharmaceutical Approvals Monthly’s Drug Review Profile stories from 2013.
Aubagio Clinical Development
A timeline chronicling the development history of Sanofi’s teriflunomide.